Kursprognose für Pacific Biosciences of California Inc (PACB)PACBPacific Biosciences of California Inc

Alphio's PACB stock price prediction model matches the current Pacific Biosciences of California Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.31 (+2.37%). The 1-week path is $1.22 (-4.36%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Pacific Biosciences (PACB) is currently not a strong buy due to its recent performance and outlook. The stock is priced at $1.40, which is below the analyst target of $1.50, indicating limited upside potential. Additionally, the company reported a significant year-to-date decline of 23.91% and has a negative forward P/E ratio of 0, reflecting uncertainty in future earnings. The recent resignation of the CEO and a downgraded revenue outlook for 2026 to $155-$165 million further complicate the investment case. The main risk lies in the company's high debt-to-equity ratio of 27223.46%, which poses a financial stability concern. Overall, while there are some positive indicators, such as a recent 5-day price increase of 3.70%, the overall sentiment and financial metrics suggest holding rather than buying at this time.

Pacific Biosciences of California Inc (PACB) last closed at $1.28, losing -5.54%. These facts feed the 1-day and 1-week PACB price prediction above.